Hitting the Bullseye: New Therapy, New HOPE

Date:
February 5 – 6, 2016

Location:
Houston Marriott - Texas Medical Center
6580 Fannin, Houston, Texas, 77030

Program Goal
Treatment decisions for cancer are becoming increasingly complicated with the rapid expansion of therapeutic options. This program will provide insights into novel approaches to diagnosis and treatment based on the mutational status of the tumor, relevant tumor markers, and the different efficacy/toxicity profiles of these new agents. The program will also highlight side effects that the majority of patients may experience with these agents. Early recognition and management of symptoms is critical in order to avoid decreased quality of life and potential interruption in treatment, both of which may affect clinical outcomes.

Educational Objectives
After attending the conference, participants should be able to:
• Describe molecular carcinogenesis including: pathways and targets unique to specific tumors
• Explain immunological treatment plans based on knowledge of cancer immunology and effects on the tumor and the microenvironment
• Discuss the evolving science of molecular tools and biomarkers to identify molecular subtypes of the major cancers
• Summarize the current and emerging treatment options for management of selected malignancies based on mutational status of the tumor, relevant tumor markers, the efficacy and toxicity profile of the agents, and the patient’s treatment history/overall health
• Recognize and manage new – mechanism based adverse effects of current immunologic and targeted agents including: GI distress, dermatologic effects, cytokine release syndrome, antiangiogenesis side effects, and autoimmune phenomenon
• Formulate patient education strategies to increase patient compliance/adherence and improve quality of care

Target Audience
This conference will be beneficial to: oncology nurses, advanced practice nurses, PharmDs, physician assistants, and research nurses/coordinators involved in the care of oncology patients undergoing treatment with novel immunotherapies and targeted agents.

Accreditation/Credit Designation

Nursing Continuing Education Contact Hours will be provided (including pharmaceutical credit hours)
• The University of Texas MD Anderson Cancer Center is an approved provider for continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation

Pharmacy Continuing Education Contact Hours will be provided
• The University of Texas MD Anderson Cancer Center is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Physician Assistants: CMEs have been requested

To be awarded continuing education credit, the following requirements must be met:
• Signed in and present for the duration of the program
• Participation in the activity learning assessment(s)
• Submission of Activity Evaluation
### Program Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 — 8:00 AM</td>
<td>Registration and Continental Breakfast Vendor Exhibits</td>
</tr>
<tr>
<td>8:00 — 8:15</td>
<td>WELCOME and Introductory Remarks—Tamara Barnes, MSN, RN, CNS, AOCNS</td>
</tr>
<tr>
<td>8:15 — 9:15</td>
<td>Cancer Genetics, Genomics</td>
</tr>
<tr>
<td></td>
<td>Julie Eggert, PhD GNP-BC, AOCN, AGN-BC, FAAN</td>
</tr>
<tr>
<td>9:15 — 10:00</td>
<td>Epigenetics and Cancer</td>
</tr>
<tr>
<td></td>
<td>Julie Eggert, PhD GNP-BC, AOCN, AGN-BC, FAAN</td>
</tr>
<tr>
<td>10:00 — 10:15</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:15 — 11:30</td>
<td>Cancer Pathways/Targets</td>
</tr>
<tr>
<td></td>
<td>Amber Johnson, PhD</td>
</tr>
<tr>
<td>11:30 — 12:00</td>
<td>Molecular Testing</td>
</tr>
<tr>
<td></td>
<td>Amber Johnson, PhD</td>
</tr>
<tr>
<td>12:00 — 1:00</td>
<td>LUNCH/Vendor Exhibits</td>
</tr>
<tr>
<td>1:00 — 3:00</td>
<td>Targeted Therapy Pharmacology</td>
</tr>
<tr>
<td></td>
<td>JoAnn Lim, Pharm D., BCOP</td>
</tr>
<tr>
<td>3:00 — 3:20</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:20 — 4:45</td>
<td>Symptom Management of Novel Agents</td>
</tr>
<tr>
<td></td>
<td>Tamara Barnes, MSN, RN, CNS, AOCNS</td>
</tr>
<tr>
<td>4:45 — 5:30</td>
<td>Acute Leukemias</td>
</tr>
<tr>
<td></td>
<td>Jeffrey C. Bryan, Pharm D.</td>
</tr>
<tr>
<td>5:30</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

### Program Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 — 8:00 AM</td>
<td>Registration and Continental Breakfast Vendor Exhibits</td>
</tr>
<tr>
<td>8:00 — 8:15</td>
<td>WELCOME — Tamara Barnes, MSN, RN, CNS, AOCNS</td>
</tr>
<tr>
<td>8:15 — 9:00</td>
<td>Update on Therapies in Solid Tumors</td>
</tr>
<tr>
<td></td>
<td>Liz Waxman, MSN, RN, ANP-BC</td>
</tr>
<tr>
<td>9:00 — 9:45</td>
<td>GI Malignancies</td>
</tr>
<tr>
<td></td>
<td>Jennifer Goldstein, MD</td>
</tr>
<tr>
<td>9:45 — 10:00</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:00 — 10:45</td>
<td>Novel Treatment Approaches to Hematologic Malignancies (cont.)</td>
</tr>
<tr>
<td></td>
<td>Lymphoma - Haleigh Mistry, MS, PA-C</td>
</tr>
<tr>
<td>10:45 — 11:30</td>
<td>Myeloma - Natalie Halladay, MS, FNP-B</td>
</tr>
<tr>
<td>11:30 — 12:00</td>
<td>Update on Clinical Application of CAR Cell Therapy</td>
</tr>
<tr>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>12:00 — 1:00</td>
<td>LUNCH</td>
</tr>
<tr>
<td>1:00 — 1:45</td>
<td>Update on Therapies in Solid Tumors (cont.)</td>
</tr>
<tr>
<td></td>
<td>Melanoma - Sapna Patel, MD</td>
</tr>
<tr>
<td>1:45 — 2:30</td>
<td>Genitourinary Malignancies</td>
</tr>
<tr>
<td></td>
<td>Mathew Campbell, MD</td>
</tr>
<tr>
<td>2:30 — 3:15</td>
<td>Gynecological Malignancies</td>
</tr>
<tr>
<td></td>
<td>Shannon Westin, MD</td>
</tr>
<tr>
<td>3:15 — 3:30</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:30 — 4:15</td>
<td>Update on Therapies in Solid Tumors (cont.)</td>
</tr>
<tr>
<td></td>
<td>Breast</td>
</tr>
<tr>
<td></td>
<td>Faith Strunk, PhD, MSN, RN, ANP-BC</td>
</tr>
<tr>
<td>4:15 — 5:00</td>
<td>Insurance Challenges in Targeted Therapy - Cynthia Kizer, RN</td>
</tr>
<tr>
<td>5:00 — 5:15</td>
<td>Evaluation / Adjourn</td>
</tr>
</tbody>
</table>

### Planning Committee

**Program Chair**

Tamara Griffey Barnes, MSN, RN, CNS, AOCNS  
Advanced Practice Nurse  
Department of Investigational Cancer Therapeutics  
The University of Texas MD Anderson Cancer Center

**Committee Members**

F. Diane Barber, Ph.D., APRN, ANP-BC, AOCNP  
Advanced Practice Nurse  
Department of Investigational Cancer Therapeutics  
The University of Texas MD Anderson Cancer Center

Katherine Mishaw, MS, RN-BC, OCN, AOCN  
Nurse Educator, Cancer Network Nursing Education  
The University of Texas MD Anderson Cancer Center

Prasamsa Ria Pandey, MSN, RN, FNP-C, AOCNP  
Advanced Practice Nurse  
Department of Investigational Cancer Therapeutics  
The University of Texas MD Anderson Cancer Center

Mildred “Millie” A. Toth, MS, RN, AOCN  
Senior Nursing Instructor  
Nursing Education  
The University of Texas MD Anderson Cancer Center
Registration Information

All Health Care Professionals (exception Industry)
- On or before Jan 15, 2016
  $100.00 for 1 day; $200.00 for 2 days
- After Jan 15, 2016
  $125.00 for 1 day; $250.00 for 2 days
- Industry (not a sponsor)
  $250.00 for 1 day; $500.00 for 2 days

Registration Methods:
- Online at www.hcons.org via online Pay PAL
- By Mail- please send payment (check or money order) to
  Houston Chapter of the Oncology Nursing Society
  PO Box 301150
  Houston Texas 77230-1150
- On-site registration only if space permits

We accept the following forms of payment
- Credit Cards (MasterCard, VISA and American Express) via online Pay PAL
- Check or money order if by mail (use attached conference registration form)
- Cash or check for on-site registration only (refer to back page for onsite pricing)

Refund/Cancellation

Refund requests must be submitted in writing. Please email your refund request to hcons.org. Refunds will be made in full (minus a $35 processing fee) when requested by December 31, 2015. Fifty percent refunds will be made (less a $35 processing fee) when requested by January 15, 2016. There will be no refunds issued after January 15, 2016.

Hotel and Transportation Arrangements: Houston visitor info.

- A block of rooms has been reserved for conference attendees at the Houston Marriott at the Texas Medical Center, 6580 Fannin, Houston, Texas, 77030
- Early hotel reservation is suggested. The Marriott reservations phone number is 713-796-0080 or 1-800-228-9290
- When you make reservations be sure to mention HCONS Presents: Hitting the Bullseye with Targeted Therapy...New Therapy, New HOPE
- Use Reference #M-3EQHBL to be assured of receiving the special meeting rate of $119/night, single or double occupancy. Please add 17% Texas State and local taxes. Rooms will be held until January 15, if not reserved will be released.

Faculty

Tamara Griffey Barnes, MSN, RN, CNS, AOCNS
Advanced Practice Provider
Investigational Cancer Therapeutics; Phase 1 Clinical Trials Program
The University of Texas MD Anderson Cancer Center

Jeffrey C. Bryan, Pharm. D.
Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center

Matthew Campbell, MD
Assistant Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center

Julie Eggert, PhD, GNP-BC, AOCN®, AGN-BC, FAAN
Professor and Coordinator Healthcare Genetics Doctoral Program
Edwards Hall School of Nursing Clemson University

Jennifer B Goldstein, MD
Instructor, GI Med Oncology - Research
The University of Texas MD Anderson Cancer Center

Natalie Halladay, MS, FNP-BC
Nurse Practitioner, Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center

Amber Johnson, Ph.D.
Precision Oncology Scientist
Institute for Personalized Cancer Therapy
The University of Texas MD Anderson Cancer Center

Cynthia Kizer, BSN, RN
Clinical Nurse Manager
Patient Access Supervisor
Clinical Center for Targeted Therapy
The University of Texas MD Anderson Cancer Center

JoAnn Lim, Pharm.D., BCOP
Clinical Pharmacy Specialist, Phase I
Division of Pharmacy
Department of Investigational Cancer Therapeutics, Phase
The University of Texas MD Anderson Cancer Center

Haleigh E Mistry, MS, PA-C
Physician Assistant, Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center

Sapna P Patel, MD
Assistant Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center

Faith A Strunk, PhD, MSN, RN, ANP-BC
CW Research Monitor, Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Elizabeth S. Waxman, MSN, RN, ANP-BC
Advanced Prac Registered Nurse, Thoracic/Head & Neck Med Onc
The University of Texas MD Anderson Cancer Center

Shannon N Westin, MD
Assistant Professor, Gyn Onc & Reproductive Med
The University of Texas MD Anderson Cancer Center

Welcome.